Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

BACKGROUND: Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC). However, acquired resistance to osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayakawa, Daisuke, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Tajima, Ken, Hidayat, Moulid, Winardi, Wira, Ihara, Hiroaki, Kanamori, Koichiro, Matsumoto, Naohisa, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Takamochi, Kazuya, Hayashi, Takuo, Suehara, Yoshiyuki, Takeda Nakamura, Ikuko, Ueno, Toshihide, Kohsaka, Shinji, Mano, Hiroyuki, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938756/
https://www.ncbi.nlm.nih.gov/pubmed/31758670
http://dx.doi.org/10.1111/1759-7714.13255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938756/
https://www.ncbi.nlm.nih.gov/pubmed/31758670
http://dx.doi.org/10.1111/1759-7714.13255

Ejemplares similares